sulabh swatchh bharat

Saturday, 16-February-2019


Handheld heart monitor can detect heart dysfunction in cancer survivors

A wireless device was comparable to cardiac MRI in accuracy when detecting heart dysfunction in childhood cancer survivors who were treated with anthracycline chemotherapy, according to a study.
Childhood cancer survivors are urged to undergo screening for the detection of heart dysfunction as a result of anthracycline-induced cardiotoxicity. However, screening with echocardiography can be highly variable and limited.  In this study, researchers evaluated the feasibility of using a wireless prototype device to detect heart abnormalities in this population.
The protype handheld device, called Vivio, collects pulse waves and phonocardiogram data form the carotid artery. The data are then wirelessly sent to a mobile device where it can be interpreted. Vivio measures the left ventricular ejection fraction (LVEF) to collect measurements in detecting signs of abnormal heart function. The study included 191 patients who were diagnosed with cancer before 22 years of age, had completed their treatment at least two years prior and been exposed to anthracycline chemotherapy.